Drug Profile


Alternative Names: Factor IX gene therapy - REGENXBIO; FIX gene therapy - REGENXBIO; scAAV 2/8-LP1-hFIXco

Latest Information Update: 11 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ReGenX Biosciences
  • Developer St. Jude Childrens Research Hospital; University College London
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Haemophilia B

Most Recent Events

  • 14 Dec 2011 Phase-I/II clinical trials in Haemophilia B in United Kingdom (IV)
  • 14 Dec 2011 Phase-I/II clinical trials in Haemophilia B in USA (IV)
  • 20 Apr 2011 Preclinical trials in Haemophilia B in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top